

Company Number: 686485

**Fadi Pharma Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 December 2025**

**Fadi Pharma Limited**  
**CONTENTS**

	<b>Page</b>
Director and Other Information	3
Director's Responsibilities Statement	4
Balance Sheet	5 - 6
Statement of Changes in Equity	7
Notes to the Financial Statements	8 - 12

**Fadi Pharma Limited**  
**DIRECTOR AND OTHER INFORMATION**

<b>Director</b>	Mohamad Fadi Al Masri
<b>Company Secretary</b>	Samar Mohd Amer Adna Qabbani
<b>Company Number</b>	686485
<b>Registered Office</b>	101 Carmody Way Fairgreen Portlaoise Laois R32 N5KV Ireland
<b>Business Address</b>	Unit 3 Ballon Carlow R32 N5KV Ireland
<b>Accountants</b>	Carrigan O'Dwyer Limited Chartered Accountants Unit 3 Enterprise House Dublin Road Kilkenny R95 K067 Ireland

# **Fadi Pharma Limited**

## **DIRECTOR'S RESPONSIBILITIES STATEMENT**

for the financial year ended 31 December 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Signed on behalf of the board**

**Mohamad Fadi Al Masri**  
**Director**

**23 February 2026**

# Fadi Pharma Limited

## BALANCE SHEET

as at 31 December 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	7	43,192	94,318
Investments	8	65,000	-
<b>Fixed Assets</b>		<b>108,192</b>	<b>94,318</b>
<b>Current Assets</b>			
Stocks	9	67,022	71,192
Debtors	10	169,528	61,293
Cash and cash equivalents		361,699	202,688
		<b>598,249</b>	<b>335,173</b>
<b>Creditors: amounts falling due within one year</b>	11	<b>(71,633)</b>	<b>(102,787)</b>
<b>Net Current Assets</b>		<b>526,616</b>	<b>232,386</b>
<b>Total Assets less Current Liabilities</b>		<b>634,808</b>	<b>326,704</b>
<b>Creditors:</b> amounts falling due after more than one year	12	<b>(68,834)</b>	<b>(79,117)</b>
<b>Net Assets</b>		<b>565,974</b>	<b>247,587</b>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Retained earnings		565,874	247,487
<b>Equity attributable to owners of the company</b>		<b>565,974</b>	<b>247,587</b>

# **Fadi Pharma Limited**

## **BALANCE SHEET**

as at 31 December 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Fadi Pharma Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 23 February 2026 and signed on its behalf by:**

**Mohamad Fadi Al Masri**  
**Director**

**Fadi Pharma Limited**  
**STATEMENT OF CHANGES IN EQUITY**

as at 31 December 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 January 2024</b>	100	167,117	167,217
Profit for the financial year	-	80,370	80,370
<b>At 31 December 2024</b>	100	247,487	247,587
Profit for the financial year	-	318,387	318,387
<b>At 31 December 2025</b>	<b>100</b>	<b>565,874</b>	<b>565,974</b>

# Fadi Pharma Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

### 1. General Information

Fadi Pharma Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 686485. The registered office of the company is 101 Carmody Way, Fairgreen, Portlaoise, Laois, R32 N5KV, Ireland. The principal activity of the company is that of a retail pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014. These are the company's first set of financial statements prepared in accordance with FRS 102.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Plant and machinery	-	12.5% Straight line
Fixtures, fittings and equipment	-	12.5% Straight line
Motor vehicles	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

#### Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the financial year in which it is receivable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

**Fadi Pharma Limited****NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 December 2025

**Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

**Borrowing costs**

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

**Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Employee benefits**

The company provides employees with the option to contribute to a PRSA on request.

**Taxation and deferred taxation**

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

**Government grants**

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

**Foreign currencies**

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

**Ordinary share capital**

The ordinary share capital of the company is presented as equity.

**3. Adoption of FRS 102**

This is the first set of financial statements prepared by Fadi Pharma Limited in accordance with accounting standards issued by the Financial Reporting Council, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A (Small Entities). The company transitioned from previously extant Irish and UK GAAP to FRS 102 Section 1A as at 1 January 2016.

<b>4. Operating profit</b>	<b>2025</b>	2024
	€	€
<b>Operating profit is stated after charging/(crediting):</b>		
Depreciation of tangible assets	<b>12,065</b>	19,878
(Profit) on disposal of tangible assets	<b>(238,360)</b>	-
Government grants received	-	(5,890)
	<u>                    </u>	<u>                    </u>

## Fadi Pharma Limited

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 December 2025

<b>5. Interest payable and similar expenses</b>	<b>2025</b>	2024
	€	€
Interest	<u>3,778</u>	<u>4,484</u>

**6. Employees**

The average monthly number of employees, including director, during the financial year was 8, (2024 - 6).

	<b>2025</b>	2024
	<b>Number</b>	Number
Pharmacist	<u>2</u>	2
Retail	<u>6</u>	4
	<u>8</u>	<u>6</u>

**7. Tangible assets**

	Plant and machinery	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
<b>Cost</b>				
At 1 January 2025	1,127	95,392	62,500	159,019
Disposals	-	-	(62,500)	(62,500)
At 31 December 2025	<u>1,127</u>	<u>95,392</u>	<u>-</u>	<u>96,519</u>
<b>Depreciation</b>				
At 1 January 2025	299	40,963	23,439	64,701
Charge for the financial year	141	11,924	-	12,065
On disposals	-	-	(23,439)	(23,439)
At 31 December 2025	<u>440</u>	<u>52,887</u>	<u>-</u>	<u>53,327</u>
<b>Net book value</b>				
At 31 December 2025	<u>687</u>	<u>42,505</u>	<u>-</u>	<u>43,192</u>
At 31 December 2024	<u>828</u>	<u>54,429</u>	<u>39,061</u>	<u>94,318</u>

**8. Investments**

	<b>Subsidiary</b>	<b>Total</b>
	<b>undertakings</b>	
	<b>shares</b>	
	€	€
<b>Investments</b>		
<b>Cost</b>		
Additions	65,000	65,000
At 31 December 2025	<u>65,000</u>	<u>65,000</u>
<b>Net book value</b>		
At 31 December 2025	<u>65,000</u>	<u>65,000</u>

**9. Stocks**

	<b>2025</b>	2024
	€	€
Finished goods and goods for resale	<u>67,022</u>	<u>71,192</u>

The replacement cost of stock did not differ significantly from the figures shown.

**Fadi Pharma Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 December 2025

<b>10. Debtors</b>	<b>2025</b>	2024
	€	€
Trade debtors	<b>39,874</b>	35,060
Amounts owed by group undertakings	<b>117,795</b>	-
Director's current account	<b>4,808</b>	(1,043)
Taxation	<b>7,051</b>	27,276
	<u><b>169,528</b></u>	<u>61,293</u>
<b>11. Creditors</b>	<b>2025</b>	2024
<b>Amounts falling due within one year</b>	<b>€</b>	<b>€</b>
Amounts owed to credit institutions	<b>12,905</b>	15,527
Net obligations under finance leases and hire purchase contracts	<b>1</b>	31,191
Trade creditors	<b>47,203</b>	40,999
Taxation	<b>7,988</b>	10,860
Accruals	<b>3,536</b>	4,210
	<u><b>71,633</b></u>	<u>102,787</u>
<b>12. Creditors</b>	<b>2025</b>	2024
<b>Amounts falling due after more than one year</b>	<b>€</b>	<b>€</b>
Bank loan	<b>68,834</b>	79,117
<b>Loans</b>		
Repayable in one year or less, or on demand	<b>12,905</b>	15,527
Repayable between one and two years	<b>12,905</b>	15,527
Repayable between two and five years	<b>55,929</b>	63,590
	<u><b>81,739</b></u>	<u>94,644</u>
<b>13. Income Statement</b>	<b>2025</b>	2024
	€	€
At 1 January 2025	<b>247,487</b>	167,117
Profit for the financial year	<b>318,387</b>	80,370
	<u><b>565,874</b></u>	<u>247,487</u>
<b>14. Capital commitments</b>		
The company had no material capital commitments at the financial year-ended 31 December 2025.		
<b>15. Director's remuneration</b>	<b>2025</b>	2024
	€	€
Remuneration	<b>46,784</b>	22,363
	<u><b>46,784</b></u>	<u>22,363</u>
<b>16. Post-Balance Sheet Events</b>		
There have been no significant events affecting the company since the financial year-end.		

**Fadi Pharma Limited**

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 31 December 2025

**17. Approval of financial statements**

The financial statements were approved and authorised for issue by the board on 23 February 2026.